Athira Pharma, Inc. (ATHA)
Athira Pharma, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Bothell, WA, US. The stock last traded at $6.75, down 6.12% on the session, giving a market capitalisation of $26.6M. On trailing twelve-month figures it carries a trailing P/E of -0.25, a net margin of 0.0%. Its beta of 2.80 implies it has historically moved more than the broad market.
Athira Pharma, Inc., a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable of crossing the blood-brain barrier. This compound is currently undergoing a Phase 3 clinical trial (LIFT-AD) and a Phase 2 clinical trial (ACT-AD) for Alzheimer's disease. Additionally, ATH-1017 is in Phase 2 clinical trials for Parkinson's disease. The company also has several product candidates in earlier, preclinical stages of development, including ATH-1019 for conditions affecting the peripheral nervous system and ATH-1020 for neuropsychiatric disorders. Founded in 2011, the organization was known as M3 Biotechnology, Inc. until it rebranded to Athira Pharma, Inc. in April 2019.
Athira Pharma, Inc. is most often compared with the following Healthcare names: